Ocular infection associated with Delftia lacustris: first report  by Sohn, Kyung Mok et al.
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etter to the Editorcular  infection  associated  with  Delftia  lacustris:
rst reportear Editor,
elftia is an aerobic, Gram-negative, oxidase-positive, non-
lucose-fermenting bacillus. Delftia species are ubiquitous in
ater and soil.1 However, they are rarely associated with
uman infections. To date, four Delftia species (D. acidovo-
ans, D. tsuruhatensis, D. lacustris, and D. litopenaei) have been
escribed. D. acidovorans (formerly known as Comamonas aci-
ovorans) and D. tsuruhatensis have been reported as causes
f human infections such as catheter-related bacteremia,
neumonia, empyema, peritonitis in a patient receiving perit-
neal dialysis, urinary tract infections, and ocular infections.2
owever, there has been no report of ocular infection by D.
acustris. Herein, we  present a patient with keratitis and prob-
ble endophthalmitis caused by D. lacustris.
A-70-year-old male farmer visited the hospital with a com-
laint of painful foreign body sensation and epiphora in his
eft eye. His symptoms developed following non-penetrating
ye trauma from a tree branch while picking red peppers two
eeks earlier. He had been taking anti-hypertensive and anti-
iabetic medications for over 30 years, but was otherwise in
ood health. On examination, visual acuity without correction
as 20/25 in his right eye and he could count ﬁngers at 30 cm
sing his left eye. The left eye demonstrated a corneal inﬁl-
rate and an approximately 1 mm corneal epithelial defect.
he right eye was clear. Cultures of corneal scrapings and
ye discharge grew Gram-negative bacilli. Isolates were iden-
iﬁed as D. acidovorans by Vitek 2 system (bioMérieux Inc.,
urham, NC, USA). Because isolation of D. acidovorans from
he eye is rare, we sent the isolate to the Infectious Dis-
ase Research Institute (IDRI) at the Asia Paciﬁc Foundation
or Infectious Diseases (APFID) for further testing. The 16S
RNA gene sequence (1276 bp) that was identiﬁed was com-
ared using BLAST searches of the GenBank and EzTaxon
ervers (http://www.ezbiocloud.net/eztaxon). The sequence
as 99.92% identical to that of D. lacustris (GenBank accession
umber EU888308). The second and the third closest matches
ere D. tsuruhatensis and D. acidovorans with 99.84% and
8.51% homology, respectively (accession numbers AB075017and AF078774). Since our strain could utilize D-mannitol and
D-malic acid (API 20 NE, bioMérieux Inc.) for growth, it was
determined to be D. lacustis. The isolates were susceptible
to aztreonam, cefepime, ceftazidime, piperacillin/tazobactam,
and carbapenems, but resistant to aminoglycosides according
to the Vitek system (bioMérieux Inc.) using 2011 Clini-
cal Laboratory Standards Institute criteria for Pseudomonas
(Table 1). The patient was initially treated with fortiﬁed topi-
cal oﬂoxacin, voriconazole, and gentamicin. Antibiotics were
switched to topical ciproﬂoxacin and systemic ceftazidime
after isolation of Delftia.  However, the patient did not respond
to therapy, and two months later underwent evisceration.
D. lacustris was ﬁrst described in 2009 in freshwater
in Denmark.3 D. lacustris and D. tsuruhatensis have 99.9%
nucleotide similarity in the 16S rRNA gene sequence, as
shown in this report. They can be differentiated based on
the use of certain carbon sources for growth, such as d-
mannitol and d-malic acid, as well as chitinase activity.3 In
this study, the isolate was determined to be D. lacustris as d-
mannitol and d-malate were utilized for growth in the API
20 NE system (bioMérieux). Shin et al. reported four possible
human infections caused by D. lacustris. However, all of these
were considered to be contaminants because only one bot-
tle out of two sets of blood cultures grew Delftia, and some
patients recovered without antibiotic therapy.4 Very recently,
we described a true bloodstream infection by D. lacustris,2
which was initially identiﬁed as D. acidovorans by Vitek 2 sys-
tem, as in this report. All four D. lacustris infections reported
by Shin et al. were also originally identiﬁed as D. acidovorans by
Vitek 2.4 This indicates that infections due to D. lacustris may
be more  common than previously thought due to misidentiﬁ-
cation by commercial systems.
According to species-independent clinical breakpoints pro-
vided by the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST, 2014), our isolate was susceptible to
aztreonam, ceftazidime, cefotaxime, piperacillin–tazobactam,
ticarcillin–clavulanate, and carbapenems, but resistant to all
aminoglycosides tested and ciproﬂoxacin. Delftia is gener-
ally considered resistant to aminoglycosides.5 Ceftriaxone
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Table 1 – Antimicrobial susceptibility proﬁles for Delftia
lacustirs.
Antibiotics MIC (g/mL) Susceptibilitya
Amikacin ≥64 R
Aztreonam 4 S
Cefepime 8 S
Ceftazidime ≤1 S
Ciproﬂoxacin 2 I
Gentamicin ≥16 R
Imipenem 1 S
Meropenem 0.5 S
Piperacillin/tazobactam ≤4 S
Ticarcillin/clavulanic acid ≤8 S
MIC, minimum inhibitory concentration; S, susceptible; R, resistant.
r
1
2
3
4
5a Because breakpoints for Delftia have not been established, this
result refers to established criteria for Pseudomonas (2011 CLSI).
and cefotaxime may be effective for the treatment of Delf-
tia infections because endocarditis caused by D. acidovorans
has been successfully controlled using ceftriaxone alone.1
Although the minimum inhibitory concentrations (MICs)
of trimethoprim–sulfamethoxazole, minocycline, and tigecy-
cline were very low, we  do not know the clinical implications
of this because there are no antibiotic susceptibility criteria or
guidelines for Delftia species.
This is the ﬁrst report of ocular infection with D. lacustris
accompanied by signiﬁcant complications. Because com-
mercial systems can misidentify Delftia species, molecular
methods such as 16S rRNA gene sequencing may be required.
Further clinical investigation of D. lacustris is necessary to
determine optimal therapy for this unusual pathogen.
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